Trade 64

BUY MRK

2.073312323 shares at $120.58 on 2026-05-26

Reasoning

Execute playbook action #111. Thesis #45: Healthcare defensive positioning. Market backdrop supports entry: (1) Healthcare -0.6% today but +2.3% over 5 days shows relative stability vs. broader volatility; (2) LLY expanding into infectious disease (shingles, superbugs) validates broader healthcare thesis expansion and demographic tailwinds; (3) 30Y yield at 5.03% favors defensive positioning over pure growth; (4) Portfolio concentration risk in tech/semiconductors argues for diversification into defensive healthcare. MRK provides pure pharma/vaccine exposure without biotech volatility. Rule #14 constrains to formation-mode sizing ($250). No prior MRK position. Execute today to establish defensive hedge and sector diversification while formation-mode window remains open under elevated-rate regime.

Thesis

MRK defensive healthcare — partial profit-take EXECUTED Aug 19 per the thesis's own terms (the Moderna-Merck cancer-vaccine Phase 3 win gapped the stock through the 10-12% take-profit band; ~45% was sold into strength). The retained core is now managed on the post-catalyst trail, not the old cost-based band. The catalyst continues to compound favorably: Aug 20 coverage frames the Phase 3 win as raising the competitive stakes in personalized cancer vaccines with Merck/Moderna in the lead — durable Keytruda-franchise validation, not a one-day squeeze. Healthcare remains the strongest 5d sector (+3.0%) despite a red Aug 20 session (-1.3% 1d). Hold the core as defensive ballast. (long, high confidence)

Outcome

7-day: -1.00% · 30-day: +3.70%

Cited evidence

Macro